On the Unique Binding and Activating Properties of Xanomeline at the M1 Muscarinic Acetylcholine Receptor

We investigated the molecular nature of the interaction between the functionally selective M 1 muscarinic acetylcholine receptor (mAChR) agonist xanomeline and the human M 1 mAChR expressed in Chinese hamster ovary (CHO) cells. In contrast to the non-subtype-selective agonist carbachol, xanomeline d...

Full description

Saved in:
Bibliographic Details
Published in:Molecular pharmacology 1998-06, Vol.53 (6), p.1120-1130
Main Authors: Arthur Christopoulos, Tracie L. Pierce, Jennifer L. Sorman, Esam E. El-Fakahany
Format: Article
Language:English
Subjects:
Animals
Atropine - pharmacology
Carbachol - pharmacology
CHO Cells
Cricetinae
Dose-Response Relationship, Drug
Humans
Muscarinic Agonists - metabolism
N-Methylscopolamine - metabolism
Nitric Oxide Synthase - metabolism
Phosphatidylinositols - metabolism
Pyridines - metabolism
Receptor, Muscarinic M1
Receptors, Muscarinic - metabolism
Thiadiazoles - metabolism
Time Factors
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:We investigated the molecular nature of the interaction between the functionally selective M 1 muscarinic acetylcholine receptor (mAChR) agonist xanomeline and the human M 1 mAChR expressed in Chinese hamster ovary (CHO) cells. In contrast to the non-subtype-selective agonist carbachol, xanomeline demonstrated M 1 mAChR binding that was resistant to extensive washout, resulting in a significant reduction in apparent N -[ 3 H]methylscopolamine saturation binding affinity in intact cells. Functional assays, using both M 1 mAChR-mediated phosphoinositide hydrolysis and activation of neuronal nitric oxide synthase, confirmed that this persistent binding resulted in elevated basal levels of system activity. Furthermore, this phenomenon could be reversed by the addition of the antagonist atropine. However, pharmacological analysis of the inhibition by atropine of xanomeline-mediated functional responses indicated a possible element of noncompetitive behavior that was not evident in several kinetic and equilibrium binding experimental paradigms. Taken together, our findings indicate for the first time a novel mode of interaction between an mAChR agonist and the M 1 mAChR, which may involve unusually avid binding of xanomeline to the receptor. This yields a fraction of added agonist that is retained at the level of the receptor compartment to persistently bind to and activate the receptor subsequent to washout. The results of the current study suggest that elucidation of the mechanism or mechanisms of interaction of xanomeline with the M 1 mAChR is particularly important in relation to the potential therapeutic use of this agent in the treatment of Alzheimer’s disease.
ISSN:0026-895X
1521-0111